Report of Foreign Issuer (6-k)
15 March 2017 - 2:21AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of
|
|
March
|
|
2017
|
Commission File Number
|
|
001-36458
|
|
|
Neovasc Inc.
|
(Translation of registrant’s name into English)
|
Suite 5138
– 13562 Maycrest Way
Richmond,
British Columbia, Canada V6V 2J7
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document
|
|
|
|
|
|
1
|
|
News
Release dated March 14, 2017 - Neovasc to Host Fourth Quarter and Fiscal Year 2016 Conference Call
|
Document 1
Neovasc to Host Fourth Quarter and Fiscal Year 2016 Conference
Call
NASDAQ, TSX: NVCN
VANCOUVER, March 14, 2017 /CNW/
-
Neovasc Inc. ("
Neovasc
"
or the "
Company
") (NASDAQ, TSX: NVCN) today announced that it will release its financial results for the fourth
quarter and fiscal year 2016 on Thursday, March 23, 2017, after markets close. The Company will subsequently hold a conference
call that same day, Thursday, March 23, 2017, at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, Chief Executive
Officer, and Mr. Chris Clark, Chief Financial Officer. A question and answer session will follow the corporate update.
Conference Call Details
|
DATE:
|
Thursday, March 23, 2017
|
TIME:
|
4:30 pm ET
|
DIAL-IN NUMBER:
|
888 390 0546 or 416 764 8688
|
A link to the live audio webcast of the conference call will
also be available on the Presentations and Events page of the Investors section of Neovasc's website at www.neovasc.com.
Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required
to hear the webcast.
A recording of the call will be available for 72 hours by
calling 888 390 0541 or 416 764 8677 and using passcode 034470#.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products include the Neovasc Reducer
™
, for the treatment of refractory angina which is
not currently available in the U.S. and has been available in Europe since 2015 and the Tiara
™
, for the transcatheter
treatment of mitral valve disease, which is currently under investigation in the U.S., Canada and Europe. The Company also sells
a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter
heart valves. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
To view the original version on PR Newswire, visit: http://www.newswire.ca/en/releases/archive/March2017/14/c2289.html
%CIK: 0001399708
For further information:
Investor Relations: Neovasc Inc.,
Chris Clark, 604 248-4138, cclark@neovasc.com
CO: Neovasc Inc.
CNW 07:00e 14-MAR-17
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Neovasc Inc.
|
|
(Registrant)
|
|
|
Date:
March 14, 2017
|
By:
|
/s/
Chris Clark
|
|
Name:
|
Chris Clark
|
|
Title:
|
Chief Financial Officer
|
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Sep 2023 to Sep 2024